Myriad Genetics Past Earnings Performance
Past criteria checks 0/6
Myriad Genetics's earnings have been declining at an average annual rate of -32.2%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 3% per year.
Key information
-32.2%
Earnings growth rate
-29.7%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | -3.0% |
| Return on equity | -33.6% |
| Net Margin | -35.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Myriad Genetics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 753 | -263 | 567 | 89 |
| 30 Sep 23 | 734 | -274 | 575 | 91 |
| 30 Jun 23 | 699 | -248 | 569 | 88 |
| 31 Mar 23 | 695 | -146 | 539 | 87 |
| 31 Dec 22 | 678 | -112 | 527 | 85 |
| 30 Sep 22 | 661 | -77 | 444 | 83 |
| 30 Jun 22 | 672 | -18 | 494 | 81 |
| 31 Mar 22 | 682 | -8 | 513 | 80 |
| 31 Dec 21 | 691 | -27 | 538 | 82 |
| 30 Sep 21 | 684 | -57 | 599 | 80 |
| 30 Jun 21 | 662 | -97 | 542 | 78 |
| 31 Mar 21 | 566 | -148 | 514 | 76 |
| 31 Dec 20 | 557 | -224 | 501 | 73 |
| 30 Sep 20 | 598 | -194 | 499 | 74 |
| 30 Jun 20 | 639 | -199 | 507 | 77 |
| 31 Mar 20 | 761 | -148 | 539 | 81 |
| 31 Dec 19 | 813 | -26 | 546 | 83 |
| 30 Sep 19 | 835 | -15 | 547 | 86 |
| 30 Jun 19 | 851 | 5 | 557 | 86 |
| 31 Mar 19 | 830 | 23 | 512 | 83 |
| 31 Dec 18 | 796 | 26 | 479 | 80 |
| 30 Sep 18 | 767 | 54 | 451 | 74 |
| 30 Jun 18 | 744 | 133 | 435 | 71 |
| 31 Mar 18 | 749 | 130 | 444 | 72 |
| 31 Dec 17 | 763 | 126 | 459 | 71 |
| 30 Sep 17 | 771 | 101 | 472 | 73 |
| 30 Jun 17 | 729 | 17 | 440 | 74 |
| 31 Mar 17 | 757 | 32 | 446 | 75 |
| 31 Dec 16 | 751 | 63 | 414 | 75 |
| 30 Sep 16 | 748 | 94 | 385 | 73 |
| 30 Jun 16 | 741 | 117 | 359 | 71 |
| 31 Mar 16 | 757 | 121 | 349 | 70 |
| 31 Dec 15 | 747 | 108 | 349 | 69 |
| 30 Sep 15 | 738 | 95 | 351 | 70 |
| 30 Jun 15 | 723 | 80 | 366 | 76 |
| 31 Mar 15 | 722 | 95 | 354 | 77 |
| 31 Dec 14 | 725 | 110 | 350 | 74 |
| 30 Sep 14 | 745 | 137 | 335 | 73 |
| 30 Jun 14 | 778 | 176 | 327 | 68 |
| 31 Mar 14 | 764 | 187 | 314 | 60 |
| 31 Dec 13 | 737 | 188 | 291 | 61 |
| 30 Sep 13 | 682 | 172 | 273 | 58 |
| 30 Jun 13 | 613 | 147 | 252 | 54 |
Quality Earnings: 0K3W is currently unprofitable.
Growing Profit Margin: 0K3W is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0K3W is unprofitable, and losses have increased over the past 5 years at a rate of 32.2% per year.
Accelerating Growth: Unable to compare 0K3W's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0K3W is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 0K3W has a negative Return on Equity (-33.62%), as it is currently unprofitable.